glp 1 schizophrenia How GLP-1 Weight-Loss Drugs Affect Appetite, Mood, and Behavior GLP-1R Agonists for Weight Loss

The amount of weight loss varies from person to person

Physiol Rev 87(4):14091439 Holst JJ (2019) Long-acting glucagon-like peptide-1 receptor agoniststatus December 2018

The short-acting nature of these preparations means timing relative to meals is clinically important

These findings are robust and supported by various predefined sensitivity tests and external data validation

Because of the differences in product half-life and therefore dosing interval, GLP-1 RAs can be classified as short- or long-acting [6]

Clinical trials of FDA-approved semaglutide and tirzepatide show average weight loss of 1521% of total body weight, far beyond what lifestyle changes alone typically achieve (individual results vary and are not guaranteed)